Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the
COMMANDER HF
trial
2015 ◽
Vol 17
(7)
◽
pp. 735-742
◽
2004 ◽
Vol 43
(5)
◽
pp. A207
2010 ◽
Vol 141
(3)
◽
pp. e39-e42
◽